![[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7](/media/k2/items/cache/2be14c7bf5e582e3d07cf6fdbe198e16_L.jpg)
[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar – medRxiv Related: Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed. Commentary on Twitter New and important data on Delta breakthrough infections, large Qatar experience and follow-up of > 1.2 million vaccinees https://t.co/2ye1Kz9OPV […]
The post [Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7% for Pfizer and 100.0% for Moderna. appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- Summary: Perioperative Management of Patients Taking Direct Oral Anticoagulants
- Summary: Community-Acquired Pneumonia
- RCT: Twice-Yearly Depemokimab Reduced Exacerbations in Severe Eosinophilic Asthma
- RCT: High-Intensity NPPV Reduced Criteria for Intubation in Acute COPD Exacerbations
- M-A | Routine anaerobic coverage for aspiration pneumonia: limited evidence of benefit
Laissez un commentaire
Assurez-vous d'entrer toutes les informations requises, indiquées par un astérisque (*). Le code HTML n'est pas autorisé.